NCT07654140RecruitingPhase 2
A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Uncontrolled Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Uncontrolled Hypertension
Source: ClinicalTrials.gov · Last updated 17 Jun 2026
Brief summary (registry, in English)
This is a multicenter, randomized, double-blind, placebo-controlled phase II study designed to explore the efficacy and safety of different doses of SAL0140 in uncontrolled hypertension.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 252 (estimated)
- First submitted
- 12 Jun 2026
- Start date
- Dec 2025
- Primary completion date
- Mar 2027
- Lead sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Diseases
- High blood pressure
- NCT number
- NCT07654140
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 252
- From Dec 2025 to the primary completion date, Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Compliance with study drug during the run-in period was less than 80% or greater than 120%.
- Patients receiving hemodialysis or adhering to strict salt restriction therapy.
Other illness
- Severe hypertension (msSBP ≥ 180 mmHg and/or msDBP ≥ 110 mmHg); malignant hypertension, hypertensive emergency, hypertensive crisis, hypertensive encephalopathy, etc.
- Hypertension complicated with the following conditions: acute coronary syndrome, myocardial infarction, percutaneous coronary intervention, stroke.
- Positive results for any of human immunodeficiency virus antibody (HIV), hepatitis C virus antibody (HCV), treponema pallidum antibody (TP); or positive hepatitis B surface antigen (HBsAg) with HBVDNA ≥ 1000 IU/mL.
- Patients with active malignant tumors.
- History of adrenal insufficiency.
- History of solid organ or bone marrow transplantation.
- Gastrointestinal diseases or post-gastrointestinal surgery.
- Known or suspected hypersensitivity to aldosterone synthase inhibitors; known or suspected contraindications or hypersensitivity to background medications.
- History of drug abuse or alcohol abuse.
Other
- Blood donation or significant blood loss.
Who the study is looking for
- Patients 18-75 years old, male or female.
- Mean seated systolic blood pressure (msSBP) at screening was ≥140 mmHg and \<180 mmHg.
- Meet either item A or B at screening: A. Uncontrolled hypertension (uHTN); B. Resistant hypertension (rHTN).
- Mean seated systolic blood pressure (msSBP) prior to randomization was ≥140 mmHg and \<180 mmHg.
- Voluntarily participate in this study and sign the informed consent form.
- Agree to comply with contraception and fertility restrictions of this study.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing Anzhen Hospital, Capital Medical University Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.